[Replacement therapy with blood components in bone-marrow depression due to cytostatic drugs (author's transl)].
Intensive cytostatic treatment is associated with severe depression of bone-marrow function, which requires treatment with specific replacement of blood components. Erythrocyte concentrates should be given "pure", without leucocytes and platelets, to prevent rapid alloimmunisation. Different separation techniques (intermittent flow and continuous flow centrifugation, double-bag platelet pheresis) provide platelet concentrates containing 2.0 to 10.0 X 10(11) platelets from a single donor. Immunization against HLA and specific antigens can be minimised by careful donor selection. Effective granulocyte support in granulocytic patients requires large doses of granulocytes given daily to compensate the deficit.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001803:Blood Transfusion; D001853:Bone Marrow / Q000187:drug effects; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000628:therapy*; D017707:Erythrocyte Transfusion; D005260:Female; D006098:Granulocytes / Q000637:transplantation*; D006801:Humans; D007937:Leukapheresis; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008297:Male; D017713:Platelet Transfusion
D000970:Antineoplastic Agents
Supportive Behandlung mit Blutkoomponenten bei zytostatisch bedingter Knochenmarksdepression.